Cryoport reports Q4 2022 revenue $60.4M, full-year record $237.3M; guides FY2023 revenue $270-290M

Cryoport, Inc.

2022-FY EPS reported -$0.93 revenue$237,277,000

Full-year 2022 revenue $237.3M, up 7% YoY; commercial therapy revenue up 27% to $16.3M.
Net loss attributable to common stockholders $45.3M ($0.93/share) vs $283.7M ($6.18/share) in 2021.
Adjusted EBITDA $13.7M for 2022, down from $21.2M in 2021; Q4 adjusted EBITDA $0.7M.
Cash and short-term investments $523.3M at year-end; repurchased 1.6M shares for $37.9M in 2022.
FY2023 revenue guidance $270-290M (18% growth at midpoint); supporting 654 clinical trials and 10 commercial therapies.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Cryoport, Inc. reported the fiscal year ended December 31, 2022 results: revenue $237.3 million. Guidance initiated.

Period: the fiscal year ended December 31, 2022
Revenue: $237.3 million
Guidance: initiated
Result: reported results

Exact text from the filing

Cryoport delivered a solid finish to 2022 with total revenue of $237.3 million

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Cryoport, Inc. reported the three months ended December 31, 2022 results: revenue $60.4 million. Guidance initiated.

Period: the three months ended December 31, 2022
Revenue: $60.4 million
Guidance: initiated
Result: reported results

Exact text from the filing

Total revenue for the fourth quarter of 2022 was $60.4 million compared to $56.4 million for the fourth quarter of 2021, a year-over-year increase of 7%

View on SEC.gov

Browse all earnings releases →

Cryoport, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-23-024795

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.